Erythropoietin: A neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy

Current Pharmaceutical Design

Volumn 19, Issue 38, 2013, Pages 6791-6801

  Merelli, Amalia ^a   Czornyj, Liliana ^b,c   Lazarowski, Alberto ^a,c  

^a University of Buenos Aires   (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c Foundation investigar   (Argentina)

Author keywords

Cerebral Hypoxia; Erythropoietin; HIF 1; Neurodegenration; P Glycoprotein; Refractory Epilepsy

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR 1; NEUROPROTECTIVE AGENT;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN HYPOXIA; CELL DEATH; CELL SURVIVAL; CORPUS CALLOSUM; DRUG RESISTANT EPILEPSY; EPILEPSY; HEMATOPOIESIS; HUMAN; INFLAMMATION; MULTIDRUG RESISTANCE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DEGENERATIVE DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; EPILEPSY; ERYTHROPOIETIN; GLUTAMIC ACID; HUMANS; HYPOXIA, BRAIN; HYPOXIA-INDUCIBLE FACTOR 1; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, ERYTHROPOIETIN;

EID: 84904577382     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319380011     Document Type: Article

References (122)

1. [1] Sharp FR, Bernaudin M. HIF-1 and oxygen sensing in the brain. Nature Reviews/ Neurosciene 2004; 5: 437-48.
2. [2] Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemicstroke: an integrated view. Trends Neurosci 22; 1999: 391-7.
3. [3] Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular pe-numbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000; 20: 1011-32.
4. [4] Semenza GL, Wang GL. A nuclear factor induced by hypoxia viade novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
5. [5] Merelli A, Caltana L, Girimonti P, Ramos AJ, Lazarowski A, Brusco A. Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hy-poxia model induced by CoCl(2) in rats. Neurotox Res 2011b; 20: 182-92.
6. [6] Semenza G. Oxygen Sensing, Homeostasis, and Disease. NEJM2011; 365: 537-47.
7. [7] Semenza G. Regulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1. Physiology 2009; 24: 97-106.
8. [8] Langmeier M, Pokorny J, Mares J, Mares P, Trojan S. Effect ofprolonged hypobaric hypoxia during postnatal development on myelination of the corpus callosum in rats, J. Hirnforsch 1987; 28 385-95.
9. [9] Langmeier M, Pokorny J, Mares J, Trojan S. Changes of the neu-ronal structure produced by prolonged hypobaric hypoxia in infant rats, Biomed Biochim Acta 1989; 48: S204-S207.
10. [10] Shukitt-Hale B, Kadar T, Marlowe BE, et al. Morphological alterations in the hippocampus following hypobaric hypoxia. Hum Exp Toxicol 1996; 15: 312-9.
11. [11] Harik SI, Hritz MA, LaManna JC. Hypoxia-induced brain angio-genesis in the adult rat, J. Physiol. (Lond.) 1995; 485: 525-30.
12. [12] Mironov V, Hritz MA, LaManna JC, Hudetz AG, Harik SI. Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res 1994; 660: 73-80.
13. [13] Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia inducible factor (HIF)-1a and HIF-2a DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284: 16767-75.
14. [14] Peers C. Oxygen-sensitive ion channels. Trends Pharmacol. Sci 1997; 18: 405-8.
15. [15] López-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N Engl J Med 2005; 353: 2042-55.
16. [16] Onodera H, Sato G, Kogure K. GABA and benzodiazepine receptors in the gerbil brain after transient ischemia: demonstration by quantitative receptor autoradiography. J Cereb Blood Flow Metab 1987; 7: 82-8.
17. [17] Pichiule P, Chavez JC, Boero J, Arregui A. Chronic hypoxia induces modification of the N-methyl-D-aspartate receptor in rat brain. Neurosci Lett 1996; 218: 83-6.
18. [18] Viapianoa MS, Mitridate de Novarab AM, Fiszer de Plazasb S, Bozzini CE. Prolonged exposure to hypobaric hypoxia transiently reduces GABAA receptor number in mice cerebral cortex. Brain Res 2001; 894: 31-6.
19. [19] Kandel ER, Squire LR. Neuroscience: breaking down scientific barriers to the study of brain and mind. Science 2000; 290: 1113-20.
20. [20] Bateman LM, Li CS, Seyal M. Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factors. Brain 2008; 131: 3239-45.
21. [21] Moseley BD, Nickels K, Britton J, Wirrell E. How common is ictal hypoxemia and bradycardia in children with partial complex and generalized convulsive seizures? Epilepsia 2010; 51: 1219-24.
22. [22] Rigau V, Morin M, Rousset MC, et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 130; 2007: 1942-56.
23. [23] Nicoletti JN, Shah SK, McCloskey DP, et al. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 2008; 151: 232-41.
24. [24] Boer K, Troost D, Spliet WG, van Rijen PC, Gorter JA, Aronica E. Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB. Acta Neuropathol 2008; 115: 683-96.
25. [25] Lorigados Pedre L, Orozco Suárez S, Morales Chacón L, et al. Neuronal death in the neocortex of drug resistant temporal lobe epilepsy patients. Neurologia 2008; 23: 555-65.
26. [26] Feast A, Martinian L, Liu J, Catarino CB, Thom M, Sisodiya SM. Investigation of hypoxia-inducible factor-1a in hippocampal sclerosis: A postmortem study. Epilepsia 2012; 53: 1349-59.
27. [27] Henshall DC, Simon RP. Epilepsy and apoptosis pathways. J Cereb Blood Flow Metab 2005; 25: 1557-72.
28. [28] Maiese K, Lia F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacological Sci 2004; 25(11): 577-83.
29. [29] Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6,484-94.
30. [30] Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97,10526-31.
31. [31] Uzum G, Sarper Diler A, Bahcekapili N, Ziya Ziylan Y. Erythropoietin prevents the increase in blood-brain barrier permeability during pentylentetrazol induced seizures. Life Sci 2006; 78: 2571-6.
32. [32] Nadam J, Navarro F, Sanchez P, et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol Disease 2007; 25: 412-26.
33. [33] Khayat R, Patt B, Hayes D. Jr. Obstructive sleep apnea: the new cardiovascular disease. Part I: obstructive sleep apnea and the pathogenesis of vascular disease. Heart Fail Rev 2009; 14: 143-53.
34. [34] Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1a expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl-hydroxylases, and mTOR. J Cell Physiol 2008; 217: 674-85.
35. [35] Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009; 16: 9848-53.
36. [36] Aviles-Reyes RX, Angelo MF, Villarreal A, Rios H, Lazarowski A, Ramos AJ. Intermittent hypoxia during sleep induces reactive glio-sis and limited neuronal death in rats: implications for sleep apnea. J Neurochem 2010; 112: 854-69.
37. [37] Jimenez-Mateos EM and Henshall DC. Seizure preconditioning and epileptic tolerance: models and mechanisms. Int J Physiol Pathophysiol Pharmacol 2009; 1: 180-91.
38. [38] Jimenez-Mateos EM, Hatazaki S, Johnson MB, et al. Hippocampal transcriptome after status epilepticus in mice rendered seizure damage-tolerant by epileptic preconditioning features suppressed calcium and neuronal excitability pathways. Neurobiol Dis 2008; 32: 442-53.
39. [39] Malow BA, Levy K, Maturen K, Bowes R. Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology 2000; 55: 1002-7.
40. [40] Chihorek AM, Abou-Khalil B, Malow BA. Obstructive sleep apnea is associated with seizure occurrence in older adults with epilepsy. Neurology 2007; 69: 1823-7.
41. [41] So EL, Sam MC, Lagerlund TL. Postictal Central Apnea as a Cause of SUDEP: Evidence From Near-SUDEP Incident. Epilepsia 2000; 41: 1494-7.
42. 42[] Ficker D, So E, Shen W, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998; Sl: 1270-74.
43. [43] Vezzani A, French J, Bartfai T and Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
44. [44] Lekera RR and Shohamib E. Cerebral ischemia and trauma— different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 2002; 39: 55-73.
45. [45] Haddad JJ and Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF- -dependent regulation of HIF-1. FEBS Lett 2001; 505: 269-74.
46. [46] Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1 and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561-7.
47. [47] Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. Interleukin 1 induces hypoxia inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000; 350(Pt 1): 307-12.
48. [48] Petito CK, Feldmann E, Pusinelli WA, Plum F. Delayed hippo-campal damage in humans following cardiorespiratory arrest. Neurology 1987; 37: 1281-6.
49. [49] Zola-Morgan S, Squire LR, Rempel NL, Clower RP, Amaral DG. Enduring memory impairment in monkeys after ischemic damage to the hippocampus. J Neurosci 1992; 12: 2582-96.
50. [50] Congar P, Gaïarsa JL, Popovici T, Ben-Ari Y, Crépel V. Permanent Reduction of Seizure Threshold in Post-Ischemic CA3 Pyramidal Neurons, J Neurophysiol 2000; 83: 2040-6.
51. 51[]Auzmendi JA, Orozco-Suárez S, Bañuelos-Cabrera I, et al. P-glycoprotein contributes to cell membrane depolarization of hippocampus and neocortex in a model of repetitive seizures induced by pentylenetetrazole in rat. Curr Pharm Des 2013 in press.
52. 52[] Wang GL and Semenza GL, General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-8.
53. [53] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
54. [54] Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51: 553-5.
55. [55] Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 2003; 17: 2614-23.
56. [56] Ivan M, Kondo K, Yang H, et al. HIF1-alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science2001; 292: 464-8.
57. [57] Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated pro-lyl hydroxylation. Science 2001; 292: 468-72.
58. [58] Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 1997; 272: 22642-7.
59. [59] Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65.
60. [60] Merelli A, Caltana L, Lazarowski A, Brusco A. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia. Drug Me-tabol Drug Interact 2011; 26: 65-9.
61. [61] Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007; 405: 1-9.
62. [62] Roesler R, Quevedo J, Schroder N. Erythropoietin, Glutamate, and Neuroprotection. NEJM 2004; 351(14): 1465-6.
63. [63] Mattson MP. Free radicals, calcium, and the synaptic plasticity-cell death continuum: emerging roles of the transcription factor NFkB. In: Bradley RJ, Harris RA & Jenner P.Eds.Int Rev Neurobiol 1998; 42: 103-68.
64. [64] Chen W, Ostrowski RP, Obenaus A, Zhang JH. Prodeath or Pro-survival: Two Facets of Hypoxia Inducible Factor-1 in Perinatal Brain Injury. Exp Neurol 2009; 216: 7-15.
65. [65] Lin J, Zheng S, Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Invest 2009; 89: 1397-409
66. [66] Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008; 85: 194-213.
67. [67] Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008; 19: 145-55.
68. [68] Browne SE. Mitochondria and Huntington’s disease pathogenesis: Insight from genetic and chemical models. Ann NY Acad Sci 2008; 1147: 358-82.
69. [69] Gil JM and Rego AC. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 2008; 27: 2803-20.
70. [70] Cha JH. Transcriptional signatures in Huntington’s disease. Prog Neurobiol 2007; 83: 228-48.
71. [71] Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
72. [72] Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab 2006; 4: 349-62.
73. [73] Gil J M, Leist M, Popovic N, Brundin P, Petersén Å. Asialo-erythropoetin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci 2004; 5: 17.
74. [74] Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276: 39469-75.
75. [75] Kon C, Keun-Hwa J, Soon-Tae L, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008; 49(10): 1723-32.
76. [76] Grammas P, Tripathy D, Sanchez A, Yin X, Luo J. Brain mi-crovasculature and hypoxia-related proteins in Alzheimer’s disease. Int J Clin Exp Pathol 2011; 4: 616-27.
77. [77] Assaraf MI, Diaz Z, Liberman A, et al. Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment. J Neuropathol Exp Neurol 2007; 66(5): 389-98.
78. [78] Lee ST, Chu K, Park JE, et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. J Neurochem 2012; 120: 115-24.
79. [79] Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene a-synuclein. PNAS 2008; 105,31: 10907-12.
80. [80] Niatsetskaya Z, Basso M, Speer RE, et al. HIF Prolyl Hydroxylase Inhibitors Prevent Neuronal Death Induced by Mitochondrial Toxins: Therapeutic Implications for Huntington’s Disease and Alzheimer’s Disease. Antioxid. Redox Signal 2010; 12, 435-43.
81. [81] Bartels AL, Willemsen ATM, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm 2008; 115: 1001-9.
82. [82] Zschiedrich K, IR König, Brüggemann N, et al. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009; 256: 115-20.
83. [83] Rapposelli S, Digiacomo M, Balsamo A. P-gp transporter and its role in neurodegenerative diseases. Curr Topics Med Chem 2009; 9: 209-17.
84. [84] Lazarowski A, Czornyj L. Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabol Drug Interact 2011; 26: 21-6.
85. [85] Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 2007; 258: 84-92.
86. [86] Caltana L, Merelli A, Lazarowski A, Brusco A. Neuronal and glial alterations due to focal cortical hypoxia induced by direct cobalt chloride (CoCl2) brain injection. Neurotox Res 2009; 15: 348-58.
87. [87] Kumral A, Tüzün F, Oner MG, Genç S, Duman N, Ozkan H. Erythropoietin in neonatal brain protection: the past, the present and the future. Brain Dev 2011; 33: 632-43.
88. [88] Lanfranconi S, Locatelli F, Corti S, et al. Growth factors in ischemic stroke. J Cell Mol Med 2011; 15: 1645-87.
89. [89] Marti HH, Gassmann M, Wenger RH, et al. Detection of erythro-poietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416-8.
90. [90] Hasselblatt M, Paulus W. Astrocytic gene expression profiling upon hypoxia. Neuroreport 2006; 17: 51-4.
91. [91] Zhou TF, Yu JG. Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia. J Surg Res 2012 (Epub ahead of print).
92. [92] Zhi-Kun S, Hong-Qi Y, Zhi-Quan W, Jing P, Zhen H, Sheng-Di C. Erythropoietin prevents PC12 cells from beta-amyloid-induced apoptosis via PI3K⁄Akt pathway. Transl Neurodegener 2012; 29; 1: 7.
93. [93] Fond G, Macgregor A, Attal J, et al. Treating patients with schizophrenia deficit with erythropoietin? Psychiatry Clin Neurosci 2012; 66: 375-82.
94. [94] Mengozzi M, Cervellini I, Villa P, et al. Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc Natl Acad Sci USA 2012; 109: 9617-22.
95. [95] Hou J, Wang S, Shang YC, Chong ZZ, Maiese K. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res 2011; 8: 220-35.
96. [96] Orimo M, Minamino T, Miyauchi H, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009; 29: 889-94.
97. 97[] Sundaresan NR, Pillai VB, Wolfgeher D, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011; 4: ra46.
98. [98] Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29: 1363-74.
99. [99] Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, JC Chavez. Neuron-Specific inactivation of the Hypoxia Inducible Factor 1 increases Brain Injury in a mouse model of transient focal cerebral ischemia. J Neurosci, 2007; 6, 27: 6320-32.
100. [100] Paschos N, Lykissas MG, Beris AE. The Role of Erythropoietin as an Inhibitor of Tissue Ischemia. Int J Biol Sci 2008; 4: 161-8.
101. [101] van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Belb F. Neuroprotective properties and mechanisms of erythro-poietin in in-vitro and in-vivo experimental models for hy-poxia/ischemia. Brain Research Review 2008; S59: 22-33.
102. [102] Chen Z-Y, Warin R, Noguchi CT. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener Dis 2006; 3: 68-75.
103. [103] Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003; 62: 228-36.
104. [104] Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alpha. Nephrol Dial Transplant 2002; 17: 8-12.
105. [105] Noguchi CT, Asavaritikrai P, Teng R, Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol 2007; 64: 159-71.
106. [106] Digicaylioglu M, Garden GA, Timberblake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulinlike growth factor I. Proc Natl Acad Sci USA 2004; 29; 101: 9855-60
107. [107] Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of p-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacool 2008; 73: 1444-53.
108. [108] Robey RW, Lazarowski A, Bates SE. P-glycoprotein- a clinical target in drug-refractory epilepsy? Mol Pharmacol 2008; 73: 1343-6.
109. [109] Hughes JR. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol Res 2008; 30: 920-5.
110. [110] Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 2010; 51: 1333-47.
111. [111] Fletcher L, Kohli S, Sprague SM, et al. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuropro-tection in stroke. Laboratory investigation. J Neurosurg 2009; 111: 164-70.
112. 112[] Fan X, van Bel F, van der Kooij MA, Heijnen CJ, Groenendaal F. Hypothermia and erythropoietin for neuroprotection after neonatal brain damage. Pediatr Res 2012. doi: 10.1038/pr.2012.139. [Epub ahead of print]
113. [113] Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuropro-tection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012; 130: 683-91.
114. [114] Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009; 12: 288-311.
115. [115] Rodrıguez JCG and Sosa Teste I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. Scientific World J 2009; 9: 970-81.
116. [116] Pankratova S, Kiryushko D, Sonn K, et al. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 2010: 133; 2281-94.
117. [117] Girgenti MJ, Hunsberger J, Duman CH, Sathyanesan M, Terwil-liger R, Newton SS. Erythropoietin Induction by Electroconvulsive Seizure, Gene Regulation, and Antidepressant-Like Behavioral Effects. Biol Psychiatry 2009; 66: 267-74.
118. [118] Sosa Teste I, Mengana Tamos Y, Rodríıguez Cruz Y, et al. Dose effect evaluation and therapeutic window of the Neuro-Epo nasal application for the treatment of the focal ischemia model in the Mongolian Gerbil. ScientificWorld J 2012; 12.
119. [119] Alcalá-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey II WH, McLoon LK. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. Journal of Drug Targeting, 2010; 18: 179-90.
120. [120] Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440-8.
121. [121] Reger MA, Watson GS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memoryimpaired older adults. J Alzheimers Dis 2008; 13: 323-31.
122. [122] Hanson LR, Frey II WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience 2008,9(Suppl 3): S5.